BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

30 ноя 2022 07:00:00 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Two Upcoming Investor Conferences

14 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

10 ноя 2022 07:00:04 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022

27 окт 2022 07:00:00 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022

05 окт 2022 07:00:00 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

07 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

09 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference

03 авг 2022 07:00:01 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

26 июл 2022 07:00:00 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

05 июл 2022 07:00:01 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

07 июн 2022 07:00:00 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

20 май 2022 07:00:00 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

09 май 2022 07:00:01 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

05 май 2022 07:00:02 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

03 май 2022 07:00:02 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

26 апр 2022 07:00:01 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology

19 апр 2022 07:05:00 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

19 апр 2022 07:00:01 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

06 апр 2022 07:00:01 Источник Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

10 мар 2022 07:04:55 Источник Nasdaq GlobeNewswire